Amarin Corp Plc (AMRN)

[Whalatane]

Ram. I still take my Vascepa ...however you and others here should be aware of the recent clinical guidance published on Healio / Cardiology

JELIS was performed in Japanese patients with high dietary intake of omega-3 fatty acids.
Thus, the generalizability of JELIS’ findings to Western populations with low dietary omega-3 intake is limited.
REDUCE-IT was performed mainly in Western populations, in patients with elevated LDL-C and triglycerides and with established atherosclerotic cardiovascular disease (ASCVD), or with diabetes and other risk factors for ASCVD.
Icosapent ethel, which was administered in 4 g doses daily, significantly reduced the risk of cardiovascular events. However, a biomarker analysis in REDUCE-IT participants revealed that the mineral oil used as a placebo may have increased the risk of ASCVD events, putting the results of REDUCE-IT into question.

( my emphasis )

The biomarker analysis they refer to I think is the Dr Ridker paper .
Capt was linking an in -vitro study I believe .
Cardiologists IMHO prescribe mainly on Outcome data ....which is why any CV data extracted from MITIGATE will be important.
MITIGATE is now 21 days past its clinical trial.gov end of study completion date .....and complete radio silence from both Kaiser and AMRN.
Lets hope they drop data like AMRN did ....with the top line R-IT results .
Kiwi